PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 1994 November; 68(11): 7598–7602.
PMCID: PMC237209

Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro.

Abstract

Group A human rotavirus strains D, Wa, DS-1, and P were originally recovered from children with diarrhea. In an attempt to attenuate virulent, wild-type human rotaviruses of major epidemiological importance for use in a live oral vaccine, two reference rotavirus strains, D and DS-1, and two laboratory-generated reassortants, Wa x DS-1 and Wa x P, were subjected to cold adaptation. Collectively, these viruses provide antigenic coverage for both of the clinically important rotavirus VP4 antigens and three of the four important rotavirus VP7 antigens. Mutants of each of these rotaviruses were selected during successive serial passage in primary African green monkey kidney cells at progressively lower suboptimal temperatures (30, 28, and 26 degrees C). The genotype of each mutant appeared to be indistinguishable from that of its wild-type, parental virus. The mutants recovered after 10 serial passages at 30 degrees C exhibited both temperature sensitivity of plaque formation (i.e., a ts phenotype) and the ability to form plaques efficiently at suboptimal temperature (i.e., a cold adaptation [ca] phenotype), in contrast to parental wild-type rotavirus. The succeeding set of 10 serial passages at 28 degrees C selected mutants that exhibited an increased degree of cold adaptation, and three of the mutants exhibited an associated increase in temperature sensitivity. Finally, in the case of three of the strains, the third successive serial passage series, which was performed at 26 degrees C, selected for mutants with an even greater degree of cold adaptation than the previous series and was associated with greater temperature sensitivity in one instance. It appeared that each of the viruses sustained a minimum of four to five mutations during the total selection procedure. The ultimate identification of candidate vaccine viruses that exhibit the desired level of attenuation, immunogenicity, and protective efficacy needed for immunoprophylaxis will require evaluation of these mutants in susceptible humans.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (985K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis. 1990 Nov;162(5):1055–1062. [PubMed]
  • Clark HF, Offit PA, Dolan KT, Tezza A, Gogalin K, Twist EM, Plotkin SA. Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses. Vaccine. 1986 Mar;4(1):25–31. [PubMed]
  • Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev. 1989 Dec;53(4):410–449. [PMC free article] [PubMed]
  • Flores J, Perez-Schael I, Blanco M, Vilar M, Garcia D, Perez M, Daoud N, Midthun K, Kapikian AZ. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. J Clin Microbiol. 1989 Mar;27(3):512–518. [PMC free article] [PubMed]
  • Gorziglia M, Larralde G, Kapikian AZ, Chanock RM. Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7155–7159. [PubMed]
  • Green KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis. 1990 Apr;161(4):667–679. [PubMed]
  • Greenberg HB, Valdesuso J, van Wyke K, Midthun K, Walsh M, McAuliffe V, Wyatt RG, Kalica AR, Flores J, Hoshino Y. Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus. J Virol. 1983 Aug;47(2):267–275. [PMC free article] [PubMed]
  • Hoshino Y, Saif LJ, Sereno MM, Chanock RM, Kapikian AZ. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol. 1988 Mar;62(3):744–748. [PMC free article] [PubMed]
  • Hoshino Y, Sereno MM, Midthun K, Flores J, Kapikian AZ, Chanock RM. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8701–8704. [PubMed]
  • Kapikian AZ, Vesikari T, Ruuska T, Madore HP, Christy C, Dolin R, Flores J, Green KY, Davidson BL, Gorziglia M, et al. An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea. Adv Exp Med Biol. 1992;327:59–69. [PubMed]
  • Matsuno S, Murakami S, Takagi M, Hayashi M, Inouye S, Hasegawa A, Fukai K. Cold-adaptation of human rotavirus. Virus Res. 1987 May;7(3):273–280. [PubMed]
  • Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol. 1985 Mar;53(3):949–954. [PMC free article] [PubMed]
  • Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol. 1986 Nov;24(5):822–826. [PMC free article] [PubMed]
  • Murphy BR, Hall SL, Kulkarni AB, Crowe JE, Jr, Collins PL, Connors M, Karron RA, Chanock RM. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994 Apr;32(1):13–36. [PubMed]
  • Offit PA, Blavat G. Identification of the two rotavirus genes determining neutralization specificities. J Virol. 1986 Jan;57(1):376–378. [PMC free article] [PubMed]
  • Padilla-Noriega L, Arias CF, López S, Puerto F, Snodgrass DR, Taniguchi K, Greenberg HB. Diversity of rotavirus serotypes in Mexican infants with gastroenteritis. J Clin Microbiol. 1990 Jun;28(6):1114–1119. [PMC free article] [PubMed]
  • Richman DD, Murphy BR. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis. 1979 May-Jun;1(3):413–433. [PubMed]
  • Shaw RD, Stoner-Ma DL, Estes MK, Greenberg HB. Specific enzyme-linked immunoassay for rotavirus serotypes 1 and 3. J Clin Microbiol. 1985 Aug;22(2):286–291. [PMC free article] [PubMed]
  • Taniguchi K, Urasawa T, Morita Y, Greenberg HB, Urasawa S. Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotype 1-, 2-, 3-, and 4-specific monoclonal antibodies to VP7. J Infect Dis. 1987 Jun;155(6):1159–1166. [PubMed]
  • Vesikari T. Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine. 1993;11(2):255–261. [PubMed]
  • Vesikari T, Isolauri E, Delem A, D'Hondt E, André FE, Zissis G. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet. 1983 Oct 8;2(8354):807–811. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)